argenx NV ADR (NASDAQ:ARGX) — Market Cap & Net Worth
Market Cap & Net Worth: argenx NV ADR (ARGX)
argenx NV ADR (NASDAQ:ARGX) has a market capitalization of $45.97 Billion ($45.97 Billion) as of October 6, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #593 globally and #288 in its home market, demonstrating a -6.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying argenx NV ADR's stock price $787.95 by its total outstanding shares 61883406 (61.88 Million).
argenx NV ADR Market Cap History: 2017 to 2026
argenx NV ADR's market capitalization history from 2017 to 2026. Data shows growth from $3.91 Billion to $56.49 Billion (48.50% CAGR). Check argenx NV ADR (ARGX) stock price for real-time trading data and today's change.
Index Memberships
argenx NV ADR is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$1.04 Trillion | 4.42% | #7 of 30 |
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 1.76% | #9 of 976 |
|
NASDAQ Composite
IXIC
|
$42.20 Trillion | 0.11% | #84 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 2.49% | #7 of 263 |
Weight: argenx NV ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
argenx NV ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how argenx NV ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see argenx NV ADR (ARGX) cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
12.53x
argenx NV ADR's market cap is 12.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
40.28x
argenx NV ADR's market cap is 40.28 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $3.91 Billion | $43.69 Million | -$33.68 Million | 89.44x | N/A |
| 2018 | $5.95 Billion | $24.57 Million | -$76.23 Million | 241.94x | N/A |
| 2019 | $9.93 Billion | $78.46 Million | -$181.21 Million | 126.60x | N/A |
| 2020 | $18.20 Billion | $41.24 Million | -$608.46 Million | 441.27x | N/A |
| 2021 | $21.67 Billion | $1.08 Billion | -$408.26 Million | 20.11x | N/A |
| 2022 | $23.44 Billion | $410.75 Million | -$709.59 Million | 57.07x | N/A |
| 2023 | $23.54 Billion | $1.23 Billion | -$295.05 Million | 19.20x | N/A |
| 2024 | $38.06 Billion | $2.19 Billion | $833.04 Million | 17.38x | 45.69x |
| 2025 | $52.04 Billion | $4.15 Billion | $1.29 Billion | 12.53x | 40.28x |
Competitor Companies of ARGX by Market Capitalization
Companies near argenx NV ADR in the global market cap rankings as of October 6, 2026. See ARGX net asset quality score to understand what proportion of total assets are financed by equity.
Key companies related to argenx NV ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $127.62 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #379 globally with a market cap of $73.47 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #611 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.76 Billion USD ( AU$85.87 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $127.62 Billion | $503.50 |
| #379 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.47 Billion | $726.47 |
| #611 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
| #455 | CSL Ltd | AU:CSL | $60.76 Billion | AU$176.99 |
argenx NV ADR Historical Marketcap From 2017 to 2026
Between 2017 and today, argenx NV ADR's market cap moved from $3.91 Billion to $ 56.49 Billion, with a yearly change of 48.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $56.49 Billion | +8.55% |
| 2025 | $52.04 Billion | +36.74% |
| 2024 | $38.06 Billion | +61.66% |
| 2023 | $23.54 Billion | +0.42% |
| 2022 | $23.44 Billion | +8.18% |
| 2021 | $21.67 Billion | +19.08% |
| 2020 | $18.20 Billion | +83.21% |
| 2019 | $9.93 Billion | +67.09% |
| 2018 | $5.95 Billion | +52.15% |
| 2017 | $3.91 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of argenx NV ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $45.97 Billion USD |
| MoneyControl | $45.97 Billion USD |
| MarketWatch | $45.97 Billion USD |
| marketcap.company | $45.97 Billion USD |
| Reuters | $45.97 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About argenx NV ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more